Clinical Trial

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Name: Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers — clinical trial record (NCT07033585)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GD-T2D

Active, Not Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-06-16.

Trial Details

NCT Number	NCT07033585
Lead Sponsor	Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Collaborators: UnitedHealthcare
Conditions	Type 2 Diabetes
Enrollment	600 participants
Start Date	2025-06-15
Primary Completion	2026-10-18 (estimated)
Study Completion	2026-11-28 (estimated)
Updated on ClinicalTrials.gov	2025-07-11